The FDA has issued guidance outlining the clinical trial requirements for new drug classes, including psychedelic drugs.
1 report, 1 independent
Updated Jul 29
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA has issued guidance outlining the clinical trial requirements for new drug classes, including psychedelic drugs.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Richard Langford provided expert comments on psychedelic drug access and is receiving feedback on clinical psychedelic programs.Sub-event
FDA guidance outlines clinical trial requirements for new drug classes.1 source
Keep exploring
The entities involved
Related events
- An Executive Order has been issued mandating accelerated research into psychedelic therapies through partnerships between various bodies.
- Faculty from Dartmouth College and the National Academy of Medicine testified regarding psilocybin research for the FDA.
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.